-
Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021
- Tjede Funk1 , Anastasia Pharris1 , Gianfranco Spiteri1 , Nick Bundle1 , Angeliki Melidou1 , Michael Carr2,3 , Gabriel Gonzalez2,3 , Alejandro Garcia-Leon4 , Fiona Crispie5 , Lois O’Connor6 , Niamh Murphy6 , Joël Mossong7 , Anne Vergison7 , Anke K. Wienecke-Baldacchino8 , Tamir Abdelrahman8 , Flavia Riccardo9 , Paola Stefanelli9 , Angela Di Martino9 , Antonino Bella9 , Alessandra Lo Presti9 , Pedro Casaca10 , Joana Moreno10 , Vítor Borges11 , Joana Isidro11 , Rita Ferreira11 , João Paulo Gomes11 , Liidia Dotsenko12 , Heleene Suija12 , Jevgenia Epstein12 , Olga Sadikova12 , Hanna Sepp12 , Niina Ikonen13 , Carita Savolainen-Kopra13 , Soile Blomqvist13 , Teemu Möttönen13 , Otto Helve13 , Joana Gomes-Dias1 , Cornelia Adlhoch1 , on behalf of COVID study groups14
-
View Affiliations Hide AffiliationsAffiliations: 1 European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden 2 National Virus Reference Laboratory (NVRL), University College Dublin, Dublin, Ireland 3 International Collaboration Unit, Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan 4 Centre for Experimental Pathogen Host Research, University College Dublin, Dublin, Ireland on behalf of the All Ireland Infectious Diseases (AIID) Cohort 5 Teagasc Food Research Centre, Moorepark, Fermoy, Ireland on behalf of the Irish Coronavirus Sequencing Consortium (ICSC) 6 Health Service Executive - Health Protection Surveillance Centre (HPSC), Dublin, Ireland 7 Health Directorate, Findel, Luxembourg 8 National Health Laboratory, Dudelange, Luxembourg 9 Istituto Superiore di Sanità, Rome, Italy 10 Directorate of Analysis and Information, Directorate-General of Health, Lisbon, Portugal 11 Bioinformatics Unit, Infectious Diseases Department, National Institute of Health Dr. Ricardo Jorge, Lisbon, Portugal 12 Health Board, Tallinn, Estonia 13 Finnish Institute for Health and Welfare (THL), Department of Health Security, Helsinki, Finland 14 The COVID study groups are listed at the end of this article under AcknowledgementsCornelia Adlhochcornelia.adlhoch ecdc.europa.eu
-
View Citation Hide Citation
Citation style for this article: Funk Tjede, Pharris Anastasia, Spiteri Gianfranco, Bundle Nick, Melidou Angeliki, Carr Michael, Gonzalez Gabriel, Garcia-Leon Alejandro, Crispie Fiona, O’Connor Lois, Murphy Niamh, Mossong Joël, Vergison Anne, Wienecke-Baldacchino Anke K., Abdelrahman Tamir, Riccardo Flavia, Stefanelli Paola, Di Martino Angela, Bella Antonino, Lo Presti Alessandra, Casaca Pedro, Moreno Joana, Borges Vítor, Isidro Joana, Ferreira Rita, Gomes João Paulo, Dotsenko Liidia, Suija Heleene, Epstein Jevgenia, Sadikova Olga, Sepp Hanna, Ikonen Niina, Savolainen-Kopra Carita, Blomqvist Soile, Möttönen Teemu, Helve Otto, Gomes-Dias Joana, Adlhoch Cornelia, on behalf of COVID study groups. Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021. Euro Surveill. 2021;26(16):pii=2100348. https://doi.org/10.2807/1560-7917.ES.2021.26.16.2100348 Received: 23 Mar 2021; Accepted: 21 Apr 2021
- Previous Article
- Table of Contents
- Next Article
Abstract
We compared 19,207 cases of SARS-CoV-2 variant B.1.1.7/S gene target failure (SGTF), 436 B.1.351 and 352 P.1 to non-variant cases reported by seven European countries. COVID-19 cases with these variants had significantly higher adjusted odds ratios for hospitalisation (B.1.1.7/SGTF: 1.7, 95% confidence interval (CI): 1.0–2.9; B.1.351: 3.6, 95% CI: 2.1–6.2; P.1: 2.6, 95% CI: 1.4–4.8) and B.1.1.7/SGTF and P.1 cases also for intensive care admission (B.1.1.7/SGTF: 2.3, 95% CI: 1.4–3.5; P.1: 2.2, 95% CI: 1.7–2.8).
Article metrics loading...
Full text loading...
References
-
Public Health England (PHE). Investigation of novel SARS-CoV-2 variant - variant of concern 202012/01. London: PHE; 2020. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/959438/Technical_Briefing_VOC_SH_NJL2_SH2.pdf
-
European Centre for Disease Prevention and Control (ECDC). Risk assessment: Risk related to spread of new SARS-CoV-2 variants of concern in the EU/EEA - first update. Stockholm: ECDC; 2021. Available from: https://www.ecdc.europa.eu/en/publications-data/covid-19-risk-assessment-spread-new-variants-concern-eueea-first-update
-
Japanese National Institute of Infectious Diseases (NIID). Brief report: new variant strain of SARS-CoV-2 identified in travelers from Brazil: Tokyo: NIID; 2021. Available from: https://www.niid.go.jp/niid/en/2019-ncov-e/10108-covid19-33-en.html
-
Faria NR, Claro IM, Candido D, Franco LAM, Andrade PS, Coletti TM, et al. Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings. Virological.org. 2021. Available from: https://virological.org/t/genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-manaus-preliminary-findings/586
-
Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv. 2020:2020.12.21.20248640. https://doi.org/10.1101/2020.12.21.20248640
-
European Centre for Disease Prevention and Control (ECDC). COVID-19 country overviews, week 12/2021, 1 April 2021. Stockholm: ECDC; 2021. Available from: https://covid19-surveillance-report.ecdc.europa.eu/archive-COVID19-reports/archive/2021W12_country_overview_report_20210331.zip
-
Horby P, Huntley C, Davies N, Edmunds J, Ferguson N, Medley G, et al. NERVTAG note on B.1.1.7 severity. London: Government Digital Service; 2021. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/955239/NERVTAG_paper_on_variant_of_concern__VOC__B.1.1.7.pdf
-
Bager P, Wohlfahrt J, Fonager J, Rasmussen M, Albertsen M, Yssing Michaelsen T, et al. Increased risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark. Preprints with the Lancet. 2021. Available from: https://ssrn.com/abstract=3792894 or http://dx.doi.org/ https://doi.org/10.2139/ssrn.3792894
-
Davies NG, Jarvis CI, Edmunds WJ, Jewell NP, CMMID COVID-19 Working Group, Diaz-Ordaz K, et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature. 2021. https://doi.org/10.1038/s41586-021-03426-1 PMID: 33723411
-
Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ. 2021;372(579):n579. https://doi.org/10.1136/bmj.n579 PMID: 33687922
-
Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021;NEJMoa2102214. https://doi.org/10.1056/NEJMoa2102214 PMID: 33725432
-
Wang P, Liu L, Iketani S, Luo Y, Guo Y, Wang M, et al. Increased resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 to antibody neutralization. bioRxiv. 2021:2021.01.25.428137. https://doi.org/10.1101/2021.01.25.428137
-
Novel variant incident management team, Public Health England with Imperial College, the University of Edinburgh, the University of Birmingham and the Wellcome Sanger Institute. New evidence on VUI-202012/01 and review of the public health risk assessment. London: Public Health England; 2020. Available from: https://khub.net/documents/135939561/338928724/New+SARS-COV-2+variant+-+information+and+risk+assessment.pdf/b56d4591-0466-1a18-28dc-010e0fdeef53?t=1608569319930
-
Public Health England (PHE). Investigation of SARS-CoV-2 variants of concern in England. London: PHE; 2021. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/961299/Variants_of_Concern_VOC_Technical_Briefing_6_England-1.pdf
-
Borges V, Sousa C, Menezes L, Gonçalves AM, Picão M, Almeida JP, et al. Tracking SARS-CoV-2 lineage B.1.1.7 dissemination: insights from nationwide spike gene target failure (SGTF) and spike gene late detection (SGTL) data, Portugal, week 49 2020 to week 3 2021. Euro Surveill. 2021;26(10):2100131. https://doi.org/10.2807/1560-7917.ES.2021.26.10.2100130 PMID: 33706862
-
Robert Koch-Institut (RKI). Risikobewertung zu COVID-19. [Risk assessment of COVID-19]. Berlin: RKI; 2021. German. Available from: https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Risikobewertung.html
-
European Centre for Disease Prevention and Control (ECDC), World Health Organization Regional Office for Europe (WHO/Europe). Methods for the detection and identification of SARS-CoV-2 variants. Stockholm and Copenhagen: ECDC and WHO/Europe; 2021. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/Methods-for-the-detection-and-identification-of-SARS-CoV-2-variants-WHO-ECDC.pdf
-
European Centre for Disease Prevention and Control (ECDC). Risk related to spread of new SARSCoV-2 variants of concern in the EU/EEA - 29 December 2020. Stockholm: ECDC; 2020. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-risk-related-to-spread-of-new-SARS-CoV-2-variants-EU-EEA.pdf
Data & Media loading...